Healthy Skepticism Library
Items published during the years 1990 to 1999
There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.
Page 4 of 24 pages ‹ First < 2 3 4 5 6 > Last ›
HSL20164
US DTC TV ads work, Web 'useless'
SCRIP 1998 Sep 16; 2370:
HSL8120
Fleming DJ, Samuels KW.
Direct-to-consumer advertising and the learned intermediary.
Hosp Pract (Minneap) 1998 Sep 15; 33:(9):129-30
HSL19887
Wise J
Aricept advertisement breached code
BMJ 1998 Sep 12; 317:(7161):7662
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1143595/
HSL6825
Hsu J.
Corporate gifts to academic researchers.
JAMA 1998 Sep 9; 280:(10):883
http://jama.ama-assn.org/cgi/content/full/280/10/883
HSL6826
Trevett KP.
Corporate gifts to academic researchers.
JAMA 1998 Sep 9; 280:(10):883-4
HSL20299
Lexchin J
Secrecy and the Health Protection Branch
CMAJ 1998 Sep 8; 159:(5):481
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1229642/
HSL8167
Carbon C, Bax RP.
Regulating the use of antibiotics in the community.
BMJ 1998 Sep 5; 317:(7159):663-5
http://www.bmj.com/cgi/content/full/317/7159/663
HSL401
Kamat VR, Nichter M.
Pharmacies, self-medication and pharmaceutical marketing in Bombay, India.
Soc Sci Med 1998 Sep; 47:(6):779-94
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-3T3SS6V-1H&_coverDate=09%2F16%2F1998&_alid=305663279&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=5925&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=77260eaace668b4e4f2bdc8361b37ee6
HSL6821
Abbott’s promotion of Claribid (clarithromycin): an example of the use of gifts
MaLAM International News 1998 Sep-Oct; 16:(9-10):1-2
HSL8129
Hewitt A, Jaquiss I.
Particle equation: company viewpoints
Pharmaceutical Executive 1998 Sep; 18:128-130, 132, 134, 136, 138
HSL8130
Petersen C.
I read it over breakfast: print proves its appeal with some all-ink DTC campaigns
Pharmaceutical Executive 1998 Sep; 18:6-8, 10, 12
HSL8131
Madell R.
High energy collision: where medical & consumer marketing intersect
Pharmaceutical Executive 1998 Sep; 18:75-112
HSL8132
Smith D.
Can DTC programs improve patient compliance?
Pharmaceutical Executive 1998 Sep; 18:14, 17
HSL8173
Wechsler J.
Safety first
Pharmaceutical Technology 1998 Sep; 22:16, 18, 20, 22, 24, 26, 28
HSL375
Silversides A.
Private sector becoming the key to research funding in Canada.
CMAJ 1998 Aug 25; 159:(4):397-8
http://www.cmaj.ca/cgi/reprint/159/4/397
HSL20011
Pemble L
New way to handle drug reps
Medical Observer 1998 Aug 2165
HSL396
Lexchin J.
Intellectual property rights and drug prices.
Lancet 1998 Aug 15; 352:(9127):582
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1B-4FWV34C-NC&_coverDate=08%2F15%2F1998&_alid=305534210&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=4886&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=85140d6e65b19947f465cc4160cdcac0
HSL20524
Jackson R, Feder G
Guidelines for clinical guidelines
BMJ 1998 Aug 15; 317:427-428
http://www.bmj.com/content/317/7156/427
HSL20173
Mahoney S
Indirect drug promotion: Media an effective way to address patients
Australian Doctor 1998 Aug 1431
HSL6820
Go on, it’s good for you
The Economist 1998 Aug 851-52
HSL20165
Mortimer D
Patients putting GPs under fat pressure
Medical Observer 1998 Aug 712
HSL19845
Vawser M
Info on medication samples
Australian Medicine 1998 Aug 37
HSL374
Smith R.
Beyond conflict of interest: Transparency is the key.
BMJ. 1998 Aug 1; 317:(7154):291-2
http://bmj.bmjjournals.com/cgi/content/full/317/7154/291
HSL6818
Consumer and physician attitudes toward direct-to-consumer advertising
: Time Inc. 1998 Aug
HSL8122
Market share plans: NCPA analysis
America's Pharmacist 1998 Aug; 120:25-27
HSL20145
Floyd K
GPs have little faith in direct to consumer ads
New Zealand Doctor 1998 July 223
HSL20510
Himmel W, Kochen MM
Doctors' perceptions of patients' wishes influence decision to prescribe drugs
BMJ 1998 July 18; 317:(211):
http://www.bmj.com/content/317/7152/211.1
HSL399
Krimsky S, Rothenberg LS.
Financial interest and its disclosure in scientific publications.
JAMA 1998 Jul 15; 280:(3):225-6
http://jama.ama-assn.org/cgi/content/full/280/3/225
HSL18027
Martin RM, Kapoor KV, Wilton LV, Mann RD.
Underreporting of suspected adverse drug reactions to newly marketed ('black triangle') drugs in general practice: observational study
BMJ 1998 Jul 11; 317:(7151):119-20
http://www.bmj.com/cgi/content/full/317/7151/119?view=long&pmid=9657787
HSL393
Lexchin J.
Residents and pharmaceutical representatives.
Can Fam Physician 1998 Jul; 44:1448:
HSL2102
Frances A, Kahn D, Carpenter D, Frances C, Docherty J.
A new method of developing expert consensus practice guidelines.
Am J Manag Care 1998 Jul; 4:(7):1023-9
http://www.ajmc.com/Article.cfm?Menu=1&ID=1662
HSL6815
Mintzes B
Paper tiger or toothless tabby? Regulation of prescription drug promotion in Canada
Vancouver: Health Policy Research Unit 1998 Jul
HSL6816
MaLAM letter follow up—MaLAM apologises but we remain concerned about thepromotion of Atarax
MaLAM International News 1998 Jul-Aug; 16:(7-8):1-5
HSL6817
Sheldon T.
Drug promotion—how ethical is direct-to-consumer advertising?
Scrip Magazine 1998 Jul-Aug; (70):21-22
www.pjbpubs.co.uk/scrip/scrhome.html
HSL6819
Milne C.
Let’s handle drug advertising carefully
Healthcare Manager 1998 Jul-Aug; 3:(5):5
HSL8125
Weiss S.
Generic drug industry: 1998 update
HealthCare Distributors 1998 Jul; 50:38-40, 42, 44
HSL10095
Brewer D.
The effect of drug sampling policies on residents' prescribing.
Fam Med 1998 Jul-Aug; 30:(7):482-6
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9669159&query_hl=2&itool=pubmed_DocSum
HSL6814
Gilbert D
Direct-to-consumer advertising of prescription medicines
Surrey, United Kingdom: PJB Publications Ltd. 1998 Jun 29
HSL383
Po AL, Zhang WY.
What lessons can be learnt from withdrawal of mibefradil from the market?
Lancet 1998 Jun 20; 351:(9119):1829-30
http://www.thelancet.com/journals/lancet/article/PIIS0140673605788000/fulltext
HSL8178
Denman J.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart pharmacy: of benefit to whom?: 3
Journal of the American Medical Association 1998 Jun 17; 279:1876
HSL8179
Sherwood LM.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart pharmacy: of benefit to whom?: 2
Journal of the American Medical Association 1998 Jun 17; 279:1876
HSL8180
Hirsch RL.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart Pharmacy: of benefit to whom?
JAMA 1998 Jun 17; 279:(23):1875-6
http://jama.ama-assn.org/cgi/content/full/279/23/1875-a
HSL8191
Hotchkiss BD, Pearson C, Lisitano R.
Pharmacy coordination of an indigent care program in a psychiatric facility.
Am J Health Syst Pharm 1998 Jun 15; 55:(12):1293-6
http://www.ajhp.org/cgi/reprint/55/12/1293
HSL405
Grossman L.
Ghostwriting.
Lancet 1998 Jun 6; 351:(9117):1741
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Grossman+L&search_within1=au&search_operator1=and&search_text2=Ghostwriting&search_within2=ti&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL372
Strandgaard S.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4; 338:(23):1697-8
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL387
Opie L.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4; 338:(23):1696-7
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL390
Meltzer JI.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4; 338:(23):
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL6812
Westfall J, McCabe J, Nicholas RA.
Drug samples: Benefit or bait? [reply]
JAMA 1998 Jun 3; 276:(21):1699
HSL6813
Wolf BL.
Drug samples: benefit or bait?
JAMA 1998 Jun 3; 279:(21):1698-9
http://jama.ama-assn.org/cgi/content/full/279/21/1698
HSL380
Roughead EE, Harvey KJ, Gilbert AL.
Commercial detailing techniques used by pharmaceutical representatives to influence prescribing.
Aust N Z J Med 1998 Jun; 28:(3):306-10
HSL409
Day R.
Pharmaceutical company promotion: striking a balance.
Aust N Z J Med 1998 Jun; 28:(3):291-3
HSL6810
Kendrick M.
The growing CME movement in Europe
Scrip Magazine 1998 Jun; (69):45-47
www.pjbpubs.co.uk/scrip/scrhome.htm
HSL8128
Reissman D.
New drugs and DTC advertising: friend or foe?
Drug Benefit Trends 1998 Jun; 10:16
HSL8148
McCarthy R.
Direct-to-consumer ads and cosmetic pharmacology
Drug Benefit Trends 1998 Jun; 10:18
HSL8221
Grauer DW.
Impact of integrated systems on pharmaceutical purchasing: are rules and regulations keeping pace?
ASHP Annual Meeting 1998 Jun; 55:
HSL388
Nightingale SL.
Advertising prescription-only drugs.
Lancet 1998 May 23; 351:(9115):1582
http://linkinghub.elsevier.com/retrieve/pii/S0140673698260211
HSL391
Medawar C.
Advertising prescription-only drugs.
Lancet 1998 May 23; 351:(9115):1584
http://www.thelancet.com/journals/lancet/article/PIIS0140673605611506/fulltext
HSL397
Levin AA.
Advertising prescription-only drugs.
Lancet 1998 May 23; 351:(9115):1583
HSL403
Inlander CB.
Advertising prescription-only drugs.
Lancet 1998 May 23; 351:(9115):1583
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Inlander+CB&search_within1=au&search_operator1=and&search_text2=Advertising+&search_within2=ti&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL406
Goldstein MR.
Advertising prescription-only drugs.
Lancet 1998 May 23; 351:(9115):1583-4
http://www.thelancet.com/search/results?search_searchuri=%2Fsearch%2Fadvanced&search_resulturi=%2Fsearch%2Fresults&search_preview=no&search_reqfirst=1&search_reqcount=20&search_submode=advanced&update_search=no&search_mode=platform&search_cluster=phoenix&search_text1=Goldstein+MR&search_within1=au&search_operator1=and&search_text2=Advertising+&search_within2=ti&search_operator2=and&search_text3=&search_within3=all&restrictterm_lancet=lancet&restrictname_lancet=lancet&restricttype_lancet=journal&restrictdesc_lancet=The+Lancet&restrictname_laneur=laneur&restricttype_laneur=journal&restrictdesc_laneur=The+Lancet+Neurology&restrictname_laninf=laninf&restricttype_laninf=journal&restrictdesc_laninf=The+Lancet+Infectious+Diseases&restrictname_lanonc=lanonc&restricttype_lanonc=journal&restrictdesc_lanonc=The+Lancet+Oncology&search_dateradio=combo&search_datecombo=0%3AALL&search_monthstartcombo=1&search_yearstart=1996&search_monthendcombo=1&search_yearend=2005&search_wordsexactly=yes&search_sort=relevance&Submit=Search
HSL412
Brown P.
Advertising prescription-only drugs.
Lancet 1998 May 23; 351:(9115):1582-3
http://linkinghub.elsevier.com/retrieve/pii/S0140673698260211
HSL400
Kelcher S, Brownoff R, Meadows LM.
Structured approach to pharmaceutical representatives. Family medicine residency program
Can Fam Physician 1998 May; 44:1053-60
HSL3758
Tremayne WH.
Dollars & sense of the health care industry.
N J Med 1998 May 01; 95:(5):71-3
HSL8193
New products spurred 11% growth in pharmaceutical sales in 1997
American Journal of Health System Pharmacy 1998 May 1; 55:880
HSL8195
Talley CR.
Confidentiality of patient records.
Am J Health Syst Pharm 1998 May 1; 55:(9):895
http://www.ajhp.org/cgi/reprint/55/9/895
HSL379
Schommer JC, Doucette WR, Mehta BH.
Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug.
Clin Ther 1998 May-Jun; 20:(3):617-32
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VRS-445RHT1-NP&_coverDate=06%2F30%2F1998&_alid=305482823&_rdoc=1&_fmt=&_orig=search&_qd=1&_cdi=6242&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=b4eac10cb17488248a3cd3fec37db9c7
HSL6808
Drug Action Programme
WHO ethical criteria for medicinal drug promotion: a strategy for review and assessment of effectiveness
Geneva: World Health Organization 1998 May
HSL6809
Lexchin J.
Re: the promotion of Duromine (phentermine)
1998 May;
HSL8119
Smallcombe P.
Case study on the deregulation of Zovirax
Irish Pharmacy Journal 1998 May; 76:136-137
HSL8121
Trend of the month: managed care, new products, and DTC efforts spur Rx sales growth
Drug Benefit Trends 1998 May; 10:10-11
HSL8174
Lyftingsmo S.
Make the drug package for the patient-not for the doctor!
International Pharmacy Journal 1998 May-Jul; 12:79
HSL8175
Hensley S.
Defying the prescription: Forget forecasts--drug sales soar under managed care
Modern Healthcare 1998 Apr 13; 28:42
HSL378
Sharp D.
A ghostly crew.
Lancet 1998 Apr 11; 351:(9109):1076
HSL8135
Ukens C.
Reaching new heights
Drug Topics 1998 Apr 6; 142:23
HSL8143
Tarlach GM.
Domino effect
Drug Topics 1998 Apr 6; 142:29
HSL411
Campbell EG, Louis KS, Blumenthal D.
Looking a gift horse in the mouth: corporate gifts supporting life sciences research.
JAMA 1998 Apr 1; 279:(13):995-9
http://jama.ama-assn.org/cgi/content/full/279/13/995
HSL413
Bero LA.
Disclosure policies for gifts from industry to academic faculty.
JAMA 1998 Apr 1; 279:(13):1031-2
http://jama.ama-assn.org/cgi/content/full/279/13/1031
HSL5377
Schiff GD, Rucker TD.
Computerized prescribing: building the electronic infrastructure for better medication usage.
JAMA 1998 Apr 1; 279:(13):1024-9
http://jama.ama-assn.org/cgi/content/full/279/13/1024
HSL6807
Hunt M
Direct-to-consumer advertising of prescription drugs
Washington, D.C.: National Health Policy Forum, George Washington University 1998 Apr
www.nhpf.org/ibonline.cfm#8-719
HSL369
Pushing ethical pharmaceuticals direct to the public.
Lancet 1998 3 28; 351:(9107):921
HSL18025
Ault A
Drugs & devices
Lancet 1998 Mar 28; 351:(9107):968
http://www.lancet.com/journals/lancet/article/PIIS0140-6736(05)60639-3/fulltext
HSL20129
Medawar C
Pushing ethical pharmaceuticals direct to public
The Lancet 1998 Mar 28; 351:(9107):921
http://www.lancet.com/journals/lancet/article/PIIS0140-6736%2805%2960594-6/fulltext
HSL8183
Gebhart F.
Annual Rx survey: new golden age
Drug Topics 1998 Mar 16; 142:71-72, 74, 76, 83
HSL416
Hoen E.
Direct-to-consumer advertising: for better profits or for better health?
Am J Health Syst Pharm 1998 Mar 15; 55:(6):594-7
http://www.ajhp.org/cgi/reprint/55/6/594.pdf
HSL8219
't Hoen E
Direct to consumer advertising: for better profits or for better health?
American Journal of Health System Pharmacy 1998 Mar 15; 55:594-597
HSL389
Melzer D.
New drug treatment for Alzheimer's disease: lessons for healthcare policy.
BMJ 1998 Mar 7; 316:(7133):762-4
http://bmj.bmjjournals.com/cgi/content/full/316/7133/762
HSL373
So AD.
Free gifts: redundancy or conundrum?
J Gen Intern Med 1998 Mar; 13:(3):213-
http://www.blackwell-synergy.com/doi/full/10.1046/j.1525-1497.1998.00058.x
HSL407
Gibbons RV, Landry FJ, Blouch DL, Jones DL, Williams FK, Lucey CR, Kroenke K.
A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts.
J Gen Intern Med 1998 Mar; 13:(3):151-4
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1998.00048.x
HSL6804
PMAC continuing health education working group at ACME Canadian day
PMAC Update 1998 Mar; 4-5
HSL6805
Lexchin J.
Re: the promotion of Atarax (hydroxyzine dichlorhydrate)
1998 Mar;
HSL6806
3M claims Duromine (phentermine) has “Proven efficacy in general practice” and “A safety profile you have come to trust” but the evidence is thin
MaLAM International News 1998 Mar-Apr; 16:(3-4):1-2
HSL8127
Gander P
What next for patient packaging?
Manufacturing Chemist 1998 Mar; 69:18-19
HSL8172
Yaguda S.
Take to the air by radio
Pharmaceutical Executive 1998 Mar; 18:72, 74, 76
HSL18026
Josefson D.
Marketing of antipsychotic drugs attacked.
BMJ 1998 Feb 28; 316:(7132):648
http://www.bmj.com/cgi/content/extract/316/7132/645/g
HSL15130
Herxheimer A.
Many NSAID users who bleed don't know when to stop.
BMJ. 1998 Feb 14; 316:(7130):492
http://www.bmj.com/cgi/content/abstract/316/7130/492
HSL8218
Simmonds H.
Prescription medicines Code of Practice Authority investigates criticisms of advertisements.
BMJ 1998 Feb 7; 316:(7129):476
HSL8166
Meyer H.
The pills that ate your profits.
Hosp Health Netw 1998 Feb 5; 72:(3):18-22
HSL19906
Garrett A
Free drugs fro the poor give doctors a PR tonic
Observer 1998 Feb 18
HSL404
Huston P, Campbell NR.
Influencing prescribing patterns.
Can Fam Physician 1998 Feb; 44:221-3,:
HSL6802
American Academy of Neurology policy on conflicts of interest: Ethics and Humanities Subcommittee.
Neurology. 1998 Feb; 50:(2):332-4
Page 4 of 24 pages ‹ First < 2 3 4 5 6 > Last ›
